Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest TB Alliance Stories

2014-02-04 12:27:12

Multi-year grant brings together non-profits, government, academia and the pharmaceutical industry to study pressing public health challenge TUCSON, Ariz., Feb. 4, 2014 /PRNewswire-USNewswire/ -- The Critical Path Institute, an independent, non-profit that catalyzes innovative ideas that accelerate the speed of drug and medical product development, today announced it has received a three-year grant from the Bill & Melinda Gates Foundation. The grant will be used to develop...

2014-01-23 11:29:46

A major trial aiming to cut the rate of tuberculosis (TB) among South Africa's gold miners did not reduce the number of cases or deaths from the disease, according to a study published in the New England Journal of Medicine. Researchers from the London School of Hygiene & Tropical Medicine say that the results demonstrate the scale of the TB problem in South African gold mines, and highlight the need for a "combination prevention" approach to improve TB control. The TB epidemic in...

2013-11-25 08:28:22

TOKYO, Nov. 25, 2013 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has become a signatory to the Tuberculosis Drug Accelerator (TBDA) partnership, a groundbreaking initiative that aims to speed up the discovery of essential new treatments for tuberculosis (TB). (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) Jointly launched in June 2012 through a collaborative agreement among seven...

2013-05-28 16:25:42

Accomplished Global Health Leader brings development and international health expertise NEW YORK, May 28, 2013 /PRNewswire-USNewswire/ -- TB Alliance, a not-for-profit organization with the mission of developing better, faster-acting, and affordable TB treatments, announces the election of Debrework Zewdie, Ph.D. to its Board of Directors. Dr. Zewdie is a deeply accomplished global health leader, and brings significant expertise to the organization. "I've dedicated my career to...

2013-04-29 08:26:20

WASHINGTON, April 29, 2013 /PRNewswire-USNewswire/ -- The Board of Directors of Accordia Global Health Foundation voted unanimously to appoint David Greeley as its new President and CEO. David brings with him more than 30 years of experience working for international development and health non-profit organizations and for the pharmaceutical company Merck & Co. Inc. "We are excited to welcome David to Accordia," said Dr. Warner C. Greene, Executive Chair of Accordia. "His impressive and...

2013-03-04 08:30:16

Former Johnson & Johnson Chairman of Pharmaceuticals brings global product development and commercialization expertise NEW YORK, March 4, 2013 /PRNewswire-USNewswire/ -- TB Alliance, a not-for-profit organization with the mission of developing better, faster-acting, and affordable TB treatments, announces the election to its Board of Directors of David Norton, former Company Group Chairman of Global Pharmaceuticals for Johnson & Johnson (J&J). Mr. Norton brings to TB Alliance...

2013-02-25 12:24:56

Global health expert and diplomat to lend skills, support to optimize new TB drug introductions WASHINGTON and NEW YORK, Feb. 25, 2013 /PRNewswire-USNewswire/ -- TB Alliance, a not-for-profit organization with the mission of developing new, improved, and affordable TB treatments, announces the election of Karl Hofmann, President and CEO of Population Services International (PSI), as President of the TB Alliance's Stakeholders Association (SHA), thereby assuming a seat on its Board of...

2012-12-21 14:41:22

4'-Phosphopantetheinyl Transferase PptT, a new drug target required for mycobacterium tuberculosis growth and persistence in vivo One third of the world is infected with the bacterium that causes tuberculosis (TB), a disease that is increasingly difficult to treat because of wide spread resistance to available drugs. Researchers from the Institute of Pharmacology and Structural Biology (CNRS, Université de Toulouse) in Toulouse (France) have identified a fresh target to...

2012-09-20 02:28:47

PARIS and NEW YORK, Sept. 20, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and the Global Alliance for TB Drug Development (TB Alliance) announced today a new research collaboration agreement to accelerate the discovery and development of novel compounds against tuberculosis (TB), a deadly infectious disease that resulted in almost 1.5 million deaths worldwide(1) in 2010. (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO ) Under the agreement, Sanofi and...

2012-09-10 23:04:28

Critical Path Institute and CDISC (Clinical Data Interchange Standards Consortium) announce the availability of a breakthrough tool to help combat tuberculosis (TB)–a persistent disease resulting in 1.7 million deaths globally each year. Tucson, AZ (PRWEB) September 10, 2012 Critical Path Institute and CDISC (Clinical Data Interchange Standards Consortium) announce the availability of a breakthrough tool to help combat tuberculosis (TB)–a persistent disease resulting in 1.7...